國家衛生研究院 NHRI:Item 3990099045/10286
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 858843      Online Users : 818
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/10286


    Title: Lymphotoxin-beta interacts with methylated EGFR to mediate acquired resistance to cetuximab in head and neck cancer
    Other Titles: Lymphotoxin-β interacts with methylated EGFR to mediate acquired resistance to cetuximab in head and neck cancer
    Authors: Hsu, DS;Hwang, WL;Yuh, CH;Chu, CH;Ho, YH;Chen, PB;Lin, HS;Lin, HK;Wu, SP;Lin, CY;Hsu, WH;Lan, HY;Wang, HJ;Tai, SK;Hung, MC;Yang, MH
    Contributors: Institute of Molecular and Genomic Medicine
    Abstract: PURPOSE: In head and neck squamous cell carcinoma (HNSCC), the incidence of RAS mutation, which is the major cause of cetuximab resistance, is relatively rare compared with the other types of cancers, and the mechanism mediating acquired resistance is unclear compared with the driver gene mutation-mediated de novo resistance. Here we investigated the driver gene mutation-independent mechanism for cetuximab resistance in HNSCC. EXPERIMENTAL DESIGN: We used the in vitro-selected and in vivo-selected cetuximab-resistant sublines of HNSCC cell lines for investigating the mechanism of acquired resistance to cetuximab. Zebrafish model was applied for evaluating the synergistic effect of combinatory drugs for overcoming cetuximab resistance. RESULTS: The cetuximab-resistant HNSCC cells undergo a Snail-induced epithelial-mesenchymal transition. Mechanistically, Snail induces the expression of lymphotoxin-beta (LTbeta), a TNF superfamily protein that activates NF-kappaB, and protein arginine methyltransferase 1 (PRMT1), an arginine methyltransferase that methylates EGFR. LTbeta interacts with methylated EGFR to promote its ligand binding ability and dimerization. Furthermore, LTbeta activates the NF-kappaB pathway through a LTbeta receptor-independent mechanism. Combination of an EGFR tyrosine kinase inhibitor and a NF-kappaB inhibitor effectively suppressed cetuximab-resistant HNSCC, and interfering with the EGFR-LTbeta interaction reverses resistance. CONCLUSIONS: Our findings elucidate the mechanism of driver gene mutations-independent mechanism of acquired resistance to cetuximab in HNSCC, and also provide potential strategies for combating cetuximab resistance.
    Date: 2017-08
    Relation: Clinical Cancer Research. 2017 Aug;23(15):4388-4401.
    Link to: http://dx.doi.org/10.1158/1078-0432.ccr-16-1955
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1078-0432&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000406680300043
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85027147569
    Appears in Collections:[Chiou-Hwa Yuh] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    PUB28196873.pdf1241KbAdobe PDF379View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback